• Maria Cristina Conti Bellocchi, Eugenio Marconato, Laura Lamonaca, Martina Cattani Mottes, Rachele Ciccocioppo, Silvia Carrara, Nicolo' de Pretis, Armando Gabbrielli, Stefano Francesco Crinò, and Luca Frulloni.
• Department of Medicine, Gastroenterology and Digestive Endoscopy Unit, Pancreas Institute, University of Verona, Verona, Italy.
• Medicine (Baltimore). 2022 Jan 28; 101 (4): e28602e28602.

AbstractThe prevalence of inflammatory bowel disease (IBD) has been described in 5% to 40% of autoimmune pancreatitis (AIP) patients. The aim of our study was to evaluate the prevalence, endoscopic features, and outcome of IBD in association with AIP.A retrospective analysis including all consecutive patients with AIP and a histological diagnosis of IBD from 2010 to 2020 was performed. Demographical data, AIP, and IBD features, as well as clinical course, were recorded.Among 267 AIP patients, 45 were diagnosed with ulcerative colitis (UC) (27 men, mean age 31.6), all with a diagnosis of type 2 AIP. The most frequent presentation of AIP was acute pancreatitis (55.5%). Both diffuse (51.1%) and focal (48.9%) pancreatic involvement were observed. The AIP relapse rate was 11.1% over a mean follow-up of 55 months. In 69% of patients, the interval time between the diagnosis of AIP and UC was <1 year. When UC was present at AIP onset, UC was in clinical remission in 50% of patients. Fecal calprotectin levels, when available, were elevated in 86.6% of these patients. Mostly, mild-moderate pancolitis was initially diagnosed (55.5%). During follow-up, escalation therapy for UC was required in 40% of patients after a mean time of 45 months. Two patients (4.4%) underwent colectomy.The prevalence of UC in AIP patients was 17%. Mild pancolitis with a low rate of colectomy was found. Greater awareness is needed to avoid a delayed diagnosis of UC, and the dosage of fecal calprotectin levels could have a role in this setting.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

30 keywords...

hide…